Spark Therapeutics Inc. has sold a rare pediatric disease priority review voucher to Irish biopharmaceutical company Jazz Pharmaceuticals PLC for $110 million.
The U.S. Food and Drug Administration granted the priority review voucher to Spark's Luxturna, a one-time gene therapy to treat patients with biallelic RPE65 mutation-associated retinal dystrophy, an eye condition related to the light sensitive film at the back of the eye.
The voucher may be redeemed for priority review of a subsequent marketing application for a different product.
Philadelphia, Pa.-based Spark Therapeutics, is a biotechnology company, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.
